RBC Capital Preview Lam Research (LRCX), Says "Don't Get Altitude Sickness Yet", Expects Positive Report
Tweet Send to a Friend
RBC Capital maintains Outperform on Lam Research (NASDAQ: LRCX), keeps price target of $120.00.Analyst Amit Daryanani comments "LRCX is positioned ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
